Oruka Therapeutics, Inc. has surged after ORKA-001 showed a half-life four times that of Skyrizi in Phase 1, targeting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results